<DOC>
	<DOCNO>NCT01966887</DOCNO>
	<brief_summary>The purpose study determine effect intracoronary SERCA2a Gene transfer cardiac volume function use multimodality cardiac imaging .</brief_summary>
	<brief_title>AAV1-CMV-Serca2a GENe Therapy Trial Heart Failure</brief_title>
	<detailed_description>The purpose gene transfer SERCA2a improve systolic diastolic function fail ventricle . Studies show reduction SERCA2a fail ventricle key factor depression contraction , restoration SERCA2a level improve leave ventricular function remodel . The aim study investigate effect adeno-associated viral vector express sarcoplasmic reticulum calcium ATPase ( SERCA2a ) , drive CMV promoter ( AAV1-CMV-SERCA2a ) , ventricular remodel patient severe heart failure use multimodality cardiac imaging . This Phase 2 monocenter double blind randomized placebo-controled , parallel study . The study enroll 44 symptomatic heart failure patient NYHA IIIb/IV , left-ventricular ejection fraction 35 % less receive optimal standard medical therapy . The absence neutralize antibody AAV1 primarily check . Seronegative patient randomize receive either 1x10e13 AAV1-CMV-Serca2a placebo single intracoronary infusion . Evolution next 6 month leave ventricular end-systolic volume ( measure 256-slices CT-scan injection 6 month later ) primary endpoint . Secondary endpoint include change LVEF , diastolic volume , VO2max , Echocardiographic remodeling , BNP , cardiac hemodynamics biological safety profile .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Patients NYHA class III / IV severe heart failure ≥ 3 month Ischemic nonischemic origin Left ventricular ejection fraction ≤35 % Patients must receive optimal ( maximum tolerate dos ) medical treatment ( diuretic , reninangiotensinaldosterone system blocker , beta blocker , ±Ivabradine ) least 1 month ( exception diuretic dose titration ) must stable . No decompensated congestive heart failure within past month With without ICD ICD implant 3 month ago , without biventricular pace RCT implant 6 month ago All woman childbearing potential must negative urine pregnancy test prior administration investigational medicinal product Patient must give write informed consent participate study &lt; 18 &gt; 80 year old AAV1 seropositivity ( titer &lt; 1:2 ) last 3 month Atrial fibrillation absence permanent ventricular pacing Coronary revascularization heart surgery pacemaker implantation &lt; 3 month Ischemic heart disease without least one coronary artery TIMI3 flow Restrictive cardiomyopathy , hypertrophic obstructive cardiomyopathy , pericardial disease , cardiac amyloidosis Heart transplant , already implant need urgently implant external ventricular assist device Myocardial infarction ( STEMI NSTEMI ) &lt; 3 month Treatment intravenous positive inotropic agent diuretic past 28 day Pregnant nursing patient Female patient childbearing age effective mean contraception Severe renal failure define creatinine clearance &lt; 30 mL/min ( last bloodwork do less 6 month ) Liver failure , chronic liver disease laboratory test &gt; 3 x N ( AST , ALT , ALP ) ) ( last bloodwork do less 6 month ) Thrombocytopenia ( &lt; 50,000/mm3 Patient treat immunosuppressant , immunodeficiency whose neutrophil count &lt; 1000 mm3 Recent sepsis ( &lt; 3 month ) Active neoplasia treat &lt; 5 year No medical insurance Patient enrol another randomize study Patient understand protocol procedure sponsor suspect poor compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Serca2a</keyword>
	<keyword>Cardiomyopathy</keyword>
</DOC>